Table 1 Correlation between m6A regulators and clinical prognosis
From: Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer
Cancer type | Number of clinical samples | Regulator | Role in PI3K/AKT pathway | Role in cancer | Associated clinical features | Prognosis | References |
|---|---|---|---|---|---|---|---|
Pancreatic cancer | – | METTL3 | Activation | Oncogene | – | Poor overall survival | [130] |
32 adjacent normal pancreatic tissues and 32 pancreatic cancer tissues | METTL3/METTL14 | Activation | Oncogene | Higher tumor stages | Poor overall survival | [131] | |
Gastric cancer | 82 matched normal and cancer tissues | ALKBH5 | Inhibition | Tumor suppressor | TNM categories and lymph node metastasis stage | Good overall survival | [136] |
72 fresh gastric cancer tissues | METTL3 | Activation | Oncogene | Lymph node metastasis | Poor overall survival | [35] | |
248 cancer tissue samples and matched adjacent tissue samples | METTL14 | Inhibition | Tumor suppressor | TNM stage | Good overall survival | [137] | |
Tissue specimens from 78 patients with diffuse gastric cancer | METTL14 | Inhibition | Tumor suppressor | Worse clinical outlook (progressed TNM status and advanced tumor stages) | Good overall survival | [23] | |
Gallbladder cancer | Surgically removed 243 gallbladder cancer and paired non-tumor tissue samples | METTL3 | Activation | Oncogene | – | Poor overall survival | [198] |
Colorectal cancer | 8 colorectal cancer and paired adjacent normal tissue specimens | METTL3 | Activation | Oncogene | – | Poor overall survival | [142] |
136 colorectal cancer and corresponding adjacent normal tissues | METTL14 | Inhibition | Tumor suppressor | Lymph node metastasis, distant metastasis and TNM stage | Good overall survival | [143] | |
Hepatocellular carcinoma | 108 pairs of hepatocellular carcinoma and adjacent normal tissues | ALKBH5 | Inhibition | Tumor suppressor | – | Good overall survival | [151] |
40 samples | METTL14 | Inhibition | Tumor suppressor | Advanced TNM stage, and distant metastasis | Relapse-free, progression-free, and disease-specific survival | [152] | |
26 tumor and adjacent matched non-tumor tissue samples | ALKBH5 | Inhibition | Oncogene | Tumor size, tumor stage, TNM stage, and microvascular invasion | Lower overall survival | [153] | |
117 pairs of primary hepatocellular carcinoma and their adjacent normal specimens | FTO | Activation | Oncogene | Metastatic nodule | Poor overall survival | [154] | |
10 paired samples were analyzed using RNA-seq and 35 paired samples were analyzed using QRT-PCR and western blot analysis | IGF2BP1 | Activation | Oncogene | Distant metastases | Poor overall survival | [155] | |
12 tumor and matched adjacent nontumor liver tissue specimens | YTHDF1 | Activation | Oncogene | Tumor weight and volume | Poor overall survival | [34] | |
Ovarian cancer | Ovarian cancer and corresponding adjacent nontumor tissues were obtained from 50 patients | METTL3/RHPN1-AS1 | Activation | Oncogene | Tumor weight and volume | Poor overall survival | [159] |
86 fresh frozen cancerous and paracancerous ovarian tissue samples | METTL3 | Activation | Oncogene | Distant metastasis and death | Worse overall and disease-free survival | [160] | |
Osteosarcoma | 40 metastatic and 64 non-metastatic osteosarcoma samples | WTAP | Inhibition | Oncogene | Tumor size, metastasis, and TNM stage | Poor overall survival | [195] |
Renal cell cancer | 24 paired kidney cancer tissues and adjacent non-cancerous tissues | IGF2BP | Activation | Oncogene | Clinical stage, nodal involvement, and distant metastasis | Poor overall survival | [168] |
28 pairs of renal cell cancer tissues and the corresponding adjacent non-cancer tissues | METTL14 | Activation | Tumor suppressor | – | Good overall survival | [167] | |
Prostate cancer | 484 non-paired prostate cancer tissue samples and 52 pair-matched samples | METTL3 | Activation | Oncogene | Lymph node metastasis | Poor overall survival | [175] |
100 fresh frozen samples of prostate tumor and adjacent normal tissues | YTHDF1 | Activation | Oncogene | High pathologic T and N stages | Poor overall survival | [176] | |
Glioblastoma | – | IGF2BP3 | Activation | Oncogene | – | Poor overall survival | [179] |
Retinoblastoma | – | METTL3 | Inhibition | Oncogene | – | Poor overall survival | [184] |
Nasopharyngeal carcinoma | Tumor tissues and matched adjacent tissues from 53 patients with nasopharyngeal carcinoma | METTL3 | Inhibition | Oncogene | Late stage and lymph node metastasis | Poor overall and disease-free survival | [188] |
105 paraffin-embedded primary nasopharyngeal carcinoma samples | YTHDC2 | Activation | Oncogene | – | Poor overall survival | [189] | |
Lung cancer | – | METTL3 | Activation | Oncogene | – | Poor overall survival | [192] |
2 lung cancer tissue samples with high CD34 expression and 2 with low CD34 expression | IGF2BP2 | Activation | Oncogene | – | Poor overall survival | [193] |